共 50 条
- [21] From triple-class exposed (TCE) to penta-exposed and triple-class refractory (PE-TCR): Real-world outcomes across a spectrum of advanced relapsed or refractory multiple myeloma (RRMM) patients (Pts) in the United States.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Delea, Thomas E.Song, XueGe, WenzhenChi, LeiEichten, CaitlinMoynahan, AaronWeycker, DerekMa, QiufeiKroog, Glenn ScottRodriguez-Lorenc, Karen
- [22] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174Krishnan, AmritaNooka, AjayChari, AjaiGarfall, AlfredMartin, ThomasNair, SandhyaLin, XiwuQi, KeqinLondhe, AnilPei, LixiaAmmann, EricKobos, RachelSmit, JenniferParekh, TrilokMarshall, AlexanderSlavcev, MaryUsmani, Saad
- [23] Effectiveness and Safety of Teclistamab in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Results of the French Real-World RetrosTECtive StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S78 - S79Perrot, AuroreHulin, CyrilleHarel, StephanieManjrah, HamzaLeveque, AntoineCroizier, CarolyneDony, ArthurMohty, MohamadManier, SalomonRoussel, MurielleOrsini-Piocelle, FrederiqueBauschert, LoicCoste, ArthurFrenzel, LaurentVincent, LaureBreal, ClaireEveillard, Jean RichardGerome, ThomasTiab, MouradChalayer, EmilieBelkhir, RakibaMariette, ClaraMoyer, PerrineBoumendil, ArianeMoreau, Philippe
- [24] Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Mateos, Maria-VictoriaChari, AjaiUsmani, Saad ZafarGoldschmidt, HartmutWeisel, KatjaQi, KeqinLondhe, AnilNair, SandhyaLin, XiwuPei, LixiaAmmann, EricKobos, RachelSmit, JenniferParekh, Trilok V.Slavcev, MaryMoreau, Philippe
- [25] Evaluation of Triple-Class Exposed (TCE) and Triple-Class Refractory (TCR) Myeloma Patients (pts) and Their Outcome: A Collaborative Study of the Argentine Group of Multiple Myeloma (GAMM)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S268 - S269Lopresti, SergioSchutz, NataliaOchoa, PaolaRemaggi, GuillerminaSardu, LautaroSeehaus, CristianFlorencia Aizpurua, MariaDuarte, PatricioShanley, ClaudiaCaeiro, GastonYantorno, SebastianCorzo, ArielCourreges, VirginiaBruno, DanielaFunes, MariaGranero, GonzaloVallejo, RodrigoFernandez, DiegoRomagnoli, CarlaGiannini, ElviraStella, FlaviaGaite, AnaPastuizaca Prado, EvelynFantl, DoroteaGarate, Gonzalo
- [26] Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple MyelomaAdvances in Therapy, 2024, 41 : 696 - 715Philippe MoreauMaría-Victoria MateosMaria Esther Gonzalez GarciaHermann EinseleValerio De StefanoLionel KarlinJoanne Lindsey-HillBritta BesemerLaure VincentSuriya KirkpatrickMichel DelforgeAurore PerrotNiels W. C. J. van de DonkCharlotte PawlynSalomon ManierXavier LeleuJoaquin Martinez-LopezFrancesca GhilottiJoris DielsRaúl MoranoClaire AlbrechtVadim StrulevImène HaddadLixia PeiRachel KobosJennifer SmitMary SlavcevAlexander MarshallKatja Weisel
- [27] Incidence of second primary malignancies (SPMs) in patients in the US with triple-class-exposed (TCE) relapsed or refractory multiple myeloma (RRMM)PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 77 - 77Ge, WenzhenArchambault, AlexiDelea, Thomas E.Lorenc, Karen RodriguezHarnett, JamesMoynahan, Aaron P.Weycker, DerekHouvras, YarivKroog, Glenn S.Wu, NingHampp, ChristianMa, QiufeiAilawadhi, Sikander
- [28] APPLYING MULTI-LEVEL NETWORK META-REGRESSION (ML-NMR) TO A CASE STUDY IN TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)VALUE IN HEALTH, 2023, 26 (06) : S283 - S283Maciel, D.Cope, S.Towle, K.Dhanda, D.Jansen, J.Malcolm, B.Klijn, S.
- [29] Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)BLOOD, 2022, 140 : 10897 - 10899Ge, WenzhenArchambault, AlexiDelea, Thomas E.Lorenc, Karen RodriguezHarnett, JamesMoynahan, AaronWeycker, DerekHouvras, YarivKroog, Glenn S.Wu, NingHampp, ChristianMa, Qiufei
- [30] Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG SitesBLOOD, 2024, 144 : 7039 - 7041Kumar, ShajiJagannath, SundarWeisel, Katja C.Dachs, Laura RosinolDimopoulos, Meletios-AthanasiosSiegel, David S.Monge, JorgeLeleu, XavierDu, Juande la Rubia, JavierLee, Jae HoonMateos, Maria-VictoriaGozzetti, AlessandroDytfeld, DominikOcio, Enrique M.Blade, JoanOzaki, ShujiNagaraj, MadhuHassan, RaflaGreen, JeannetteKroog, Glenn S.Lorenc, Karen RodriguezHampp, ChristianMa, QiufeiDurie, Brian G. M.